RUNX1 and acute myeloid leukemia: In pediatric t(8;21) AML, transcript variants containing multiple in-frame-deletions involving exons 2–5 of AML1 and exon 2 and 3 of ETO were identified, which displayed both activating and repressive effects on AML1-mediated GM-CSF transactivation [30].